Kalorama: Five Reasons for Optimism in Next Generation Sequencing
NEW YORK, Feb. 25, 2015 /PRNewswire/ -- Kalorama Information says the market for sequencing systems including next generation models grew to 2.2 billion dollars in 2014, and is expected to continue to grow driving by the increasing use of the systems for clinical diagnostics. The healthcare market research firm said that over the years, the next generation sequencing (NGS) field has gone through periods of excitement, sometimes referred to as hype, followed by periods of disappointment as the hoped for advances have not materialized as quickly as hoped or promised. There is now a much more realistic basis for market growth, and the firm cites five factors in particular. The finding was made in Kalorama Information's Next Generation Sequencing Markets 2015.
The report can be obtained at: http://www.kaloramainformation.com/Generation-Sequencing-Systems-8743599/.
The promise of next generation sequencing has attracted many companies, researchers, investors, and others. DNA sequencing has already become a large market, and clinical applications of DNA sequencing are being developed and commercialized. Evidence of the promise and current excitement with sequencing can be seen with many recent events:
- Growth: The sequencing market is growing rapidly. In October 2014, market leader Illumina raised the company's full year 2014 guidance for investors to a revenue growth for the company of approximately 30% over the previous year.
- Top Company Moves: Roche, the leader in IVD has made several investments. Roche and Foundation Medicine announced an agreement that is worth up to $1.2 billion. Roche agreed to acquire a majority interest in Foundation Medicine for approximately $780 million. Roche also agreed to invest $250 million in Foundation Medicine, and to fund potentially more than $150 million of R&D. This month, Roche announced it would buy German genomics firm Signature Diagnostics, and the company has acquired Bina Informatics, which makes sequencing-related software.
- Companies Raise Money: In just the first part of January 2015, 10X Genomics closed a $55.5 million Series B financing and Invitae filed for an initial public offering, These follow a busy 2014 year that saw many investments in next generation sequencing companies and companies with products or services related to next generation sequencing.
- Pharma Gets Involved: Companies in the pharmaceutical industry have recognized the potential benefits of next generation sequencing as a research and development tool. During just part of 2015, Genentech announced two agreements, and Pfizer announced one.
- The Clinic Awaits: While next generation sequencing has been used for some clinical applications for a while, this is becoming more widespread. Illumina's MiSeqDx was the first cleared in vitro diagnostic (IVD) next generation sequencing system. MiSeqDx is also CE marked, and FDA-cleared tests are currently available on this platform.
Kalorama Information says these are just selected highlights of recent activities in this rapidly changing market.
The entire market is broken out in detail in Kalorama's Next Generation Sequencing Markets 2015. The report includes detailed tables indicating the activities of competitors in the market. The report breaks out system, consumable and service segments and provides information on brand ownership and regional installed base of sequencers. The report can be purchased at: http://www.kaloramainformation.com/Generation-Sequencing-Systems-8743599/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
Logo - http://photos.prnewswire.com/prnh/20140801/132634
SOURCE Kalorama Information
Related Links
http://www.kaloramainformation.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article